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During worldwide rollout of SARS-CoV-2 vaccines it is vital 
to understand how vaccination influences immune responses 
and protection among those who have had prior natural 
SARS-CoV-2 infection. This is a knowledge-gap since a history 
of previous infection was an exclusion criterion in Phase III 
vaccine trials (1). Countries have adopted diverse approaches, 
including the UK policy to maximize deployment of first 
doses to the largest possible numbers by extending the time 
interval to second dose. At the end of 2020, it became appar-
ent several virus variants had emerged (2, 3) and that these 
might impact vaccine rollout. The B.1.1.7 variant, possessing 
the spike N501Y mutation, first emerged in the UK in Decem-
ber 2020 and spread rapidly (4). Additional variants of con-
cern (VOC) include the B.1.351 variant, which emerged at 
about the same time in South Africa and the P.1 variant that 
emerged in January 2021 in Brazil. Both have the N501Y 
mutation, in addition to E484K, the latter implicated in es-
cape from neutralizing antibody (nAb) (5, 6). 
The Pfizer/BioNTech mRNA vaccine BNT162b2 encodes a 
prefusion stabilized, membrane-anchored SARS-CoV-2 full-
length spike protein modified by two proline substitutions (1, 
7, 8). A two-dose regimen of 30 μg BNT162b2, 21d apart, con-
fers 95% protection against Wuhan-Hu-1 SARS-CoV-2 (1), 
eliciting high nAb titers, as well as CD4 cell and CD8 re-
sponses (8). When given as a single 60 μg dose, BNT162b1 
induced virus Ab neutralization, but T cell responses were re-
duced compared with the standard prime-boost regime (8). 
Single 30 μg dose, BNT162b1 was not reported beyond d21. 
However, the cumulative incidence of COVID-19 cases among 
21,676 placebo and 21,699 vaccine recipients diverged 12 days 
after the first dose, indicating possible early-onset first dose 
protection (1). For those who were previously infected, single 
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SARS-CoV-2 vaccine rollout has coincided with the spread of variants of concern. We investigated if single 
dose vaccination, with or without prior infection, confers cross protective immunity to variants. We 
analyzed T and B cell responses after first dose vaccination with the Pfizer/BioNTech mRNA vaccine 
BNT162b2 in healthcare workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-
CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody 
secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351. 
By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against 
variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated or unchanged T cell responses 
depending on human leukocyte antigen (HLA) polymorphisms. Single dose vaccination with BNT162b2 in 
the context of prior infection with a heterologous variant substantially enhances neutralizing antibody 
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dose vaccination may act as a boost following natural infec-
tion. Therefore, we aimed to test the impact of prior SARS-
CoV-2 infection on T cell and B cell responses to first dose 
vaccination. 
To do this, we analyzed T and B cell immunity after the 
first 30 μg dose of the Pfizer/BioNTech mRNA vaccine 
BNT162b2, in a cohort of UK hospital healthcare workers 
(HCW) (9–12). The COVIDsortium HCW cohort has been 
studied longitudinally since the end of March 2020, provid-
ing accurate infection and immune history in the context of 
genotyping, including HLA imputation (10–12). Our aim was 
to compare T and B cell immunity after a first dose of vaccine 
in December 2020, in individuals post-infection (after natural 
infection), vaccinated post-infection (vaccination in the con-
text of prior SARS-CoV-2 infection) and vaccinated naïve (sin-
gle dose vaccination). We wished to explore if there is 
evidence for altered T cell recognition of the B.1.1.7 and 
B.1.351 variants, and in particular, of the N501Y mutation 
shared by several VOC. 
The UK has deployed a heterodox vaccination regimen to 
maximize immune protection and slow spread of the B.1.1.7 
lineage, giving an initial 30 μg dose of BNT162b2, followed by 
boosting up to 12 weeks later (13). A cross-sectional sub-study 
(n = 51) of the existing longitudinal HCW cohort (9–12) was 
recruited 22d (±2) after the first dose. After the start of the 
study, the majority of acute infections had already occurred 
among this cohort (11). At the time of receiving their first vac-
cine dose in December 2020, 25 individuals were approxi-
mately 39 weeks post SARS-CoV-2 infection with the Wuhan 
Hu-1 strain and prior to the emergence of VOC and 26 were 
confirmed uninfected, having tested negative in longitudinal 
serology for spike and nucleocapsid (N) (table S1 and fig. S1). 
We first measured SARS-CoV-2 N antibody longitudinally 
up to 16–18 weeks, then at 28–30 weeks and finally 42 weeks 
post-recruitment to confirm that there was no laboratory ev-
idence of new infection at the time of drawing blood for the 
vaccine study at 42 weeks: none of the previously uninfected 
HCW had become seropositive (Fig. 1A). T cell responses to 
spike protein and MEP (mapped epitope peptides) in either 
post infection, vaccinated post infection or vaccinated naïve 
individuals were compared (Fig. 1B). Ninety six percent 
(22/23) of vaccinated post infection individuals made a T cell 
response to spike protein compared to 70% (16/23) of vac-
cinated naïve individuals, with a 4-fold increase in magnitude 
of T cell response. Furthermore, while the T cell response to 
spike protein in vaccinated naïve individuals increased (p = 
0.0440), it was lower than those of vaccinated post infection 
individuals (p = 0.0557) (Fig. 1C). As expected, there was no 
significant change in T cell response to N (a measure of im-
munity to natural infection) (fig. S2A). 
Paired analysis of T cell immunity to spike protein in pre-
viously uninfected individuals, analyzed at the 16–18 week 
timepoint and 3 weeks after vaccination, showed a signifi-
cantly increased response (p = 0.0089) (Fig. 1D). Three indi-
viduals who previously showed a response, despite lack of 
laboratory evidence for infection (therefore presumably a 
cross-reactive response to an endemic human coronavirus) 
showed an unchanged or decreased response to spike after 
vaccination. 
The size of the SARS-CoV-2 S1 specific memory B cell pool 
was investigated by B cell ELISpot (Fig. 1E and fig. S2B). As 
for T cell responses, the number of S1 specific IgG+ antibody 
secreting cells (ASC) was far greater in vaccinated post infec-
tion individuals compared with vaccinated naïve individuals 
(p < 0.0001). Prior infection generated a 63-fold increase in 
S1 specific ASC. There were no pre-existing S1 specific ASC in 
uninfected HCW pre-vaccination. Twenty of 22 vaccinated 
naïve individuals had detectable S1 specific ASC comprising 
0.02% to 1.54% of the memory B cell (MBC) pool. By compar-
ison, all vaccinated post infection individuals had detectable 
S1 specific ASCs (1.90–50% of MBC pool). We previously re-
ported (14), spike receptor binding domain (RBD) enhanced 
Ab responses in the vaccinated post infection group. In this 
work, the vaccination naïve group attained similar antibody 
titers to the post infection group at 16–18 and 28–30 weeks 
(Fig. 1F). Vaccinated naïve individuals made a lower nAb re-
sponse to WT virus than seen following natural infection at 
16–18 weeks although this did not achieve statistical signifi-
cance. In line with the findings for MBC and RBD binding, 
there was a significantly enhanced nAb response in vac-
cinated post infection individuals compared with the vac-
cinated naïve group (Fig. 1G), the mean value being 25,273 
compared to 420, that is, a 60-fold increase. To put this in 
context, these values are 43-fold higher than the values rec-
orded after 2 vaccine doses in the Phase 1 trial (7). There was 
no correlation between the magnitude of the spike protein T 
cell response and the percentage of S1 specific ASC (Fig. 1H). 
As expected, there was a positive correlation between the per-
centage of S1 specific ASC and the serum titer of RBD anti-
body in the vaccinated post infection individuals (r = 0.6502; 
p = 0.0008) (Fig. 1I). After vaccination, two previously in-
fected individuals showed lower percentages of S1 specific 
memory B cells and reduced serum RBD specific antibody 
levels than the rest of the group; prior infection involving 
case-definition symptoms tended to be associated with a 
higher specific B cell frequency than milder disease (Fig. 1F 
and fig. S2C). These individuals who, despite infection, had 
also not shown a detectable T cell response (one never sero-
converted and the other rapidly became seronegative during 
longitudinal follow up) had a poor or absent response to in-
fection that was only minimally overcome by vaccination. 
The data in Fig. 1 indicate that there is a strong prime-
boosting effect of prior infection on single dose vaccination. 
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RBD, and nAb responses than for T cell response frequency. 
Furthermore, there was no correlation between S1 ASC fre-
quency and T cell response frequency (Fig. 1H). There is, how-
ever, a correlation between S1 ASC and RBD antibody titers, 
indicating that individuals with higher numbers of MBC 
make higher antibody responses, and individuals who had ex-
perienced infection clustered at the higher end of this re-
sponse (Fig. 1I). 
Shortly before the vaccination program was initiated, sev-
eral VOC emerged, including the B.1.1.7 VOC. This variant has 
nine mutations in the spike protein. Several studies have re-
ported weaker nAb responses to B.1.1.7 relative to the previ-
ously circulating Wuhan-Hu-1 strain (2–6, 15–18). The 
majority of SARS-CoV-2 immune naïve individuals made no 
nAb response to the B.1.1.7 (18/20) and B.1.351 (17/20) vari-
ants after single dose vaccination. In contrast, almost all vac-
cinated post infection individuals made a strong nAb 
response to the B.1.1.7 (24/24) and B.1.351 (23/24) variants af-
ter a single dose vaccination with a 46-fold (B.1.1.7) and 63-
fold (B.1.351) increase in mean nAb IC50 in vaccinated post 
infection compared to vaccinated naïve individuals. In a 
paired analysis, we observed in vitro significantly reduced 
nAb potency to authentic B.1.1.7 variant virus (>24.7-fold 
lower than response to Wuhan Hu-1, p < 0.0001) in sera from 
individuals with a past medical history of natural infection 
(Fig. 2B). Worryingly, after single dose vaccination, 90% 
(18/20) of vaccinated naïve individuals showed no detectable 
nAbs (IC50 < 50) against B.1.1.7 (mean IC50 37, range 0 to 
184; p = 0.2090), but did show demonstrable nAb responses 
to Wuhan Hu-1 SARS-CoV-2 virus (mean IC50 420, range 80 
to 2,004; p = 0.0046). In contrast, all vaccinated post infec-
tion individuals responded to single dose vaccination with 
substantially enhanced nAb responses, neutralizing not just 
Wuhan Hu-1 SARS-CoV-2 (mean IC50 25,273; range IC50 581 
to 76,369), but also the B.1.1.7 (mean IC50 1717; range: IC50 
52 to 4919) and B.1.351 (mean IC50 5451; range: IC50 41 to 
20,411) variants (Fig. 2, A and B, and fig. S3). We show a 14.7-
fold reduction in neutralization (IC50) responses in SARS-
CoV-2 B.1.1.7 variant compared to Wuhan Hu-1 virus in vac-
cinated post infection individuals. However, despite this fall 
the majority (22/24) remain within a “protective threshold.” 
This was not the case for vaccinated naïve individuals. There 
was a 11.4-fold reduction in neutralization (IC50) responses 
against SARS-CoV-2 B.1.1.7 variant (mean, 37) compared to 
Wuhan Hu-1 virus (mean, 420) resulting in the majority of 
individuals (19/20) falling below the “protective threshold.” 
This result was mirrored in the SARS-CoV-2 S1 specific 
memory B cell pool where reduced numbers of S1 specific 
IgG+ ASC are seen (in vaccinated naïve individuals compared 
to vaccinated post infection individuals) responding to S1 an-
tigen containing the N501Y, K417N and E484K mutations. 
Prior infection substantially enhances the specific memory B 
cell pool after single dose vaccination (Fig. 2C). We looked at 
correlations between RBD binding antibodies, B cell re-
sponses, T cell responses and IC50, comparing neutralization 
of Wuhan Hu-1, B.1.1.7 and B.1.315 live virus (Fig. 2D). Despite 
the lower neutralization of B.1.1.7 and B.1.315 variants, the 
pattern was retained of strong correlation between RBD an-
tibody titer. S1 specific B cell frequency and neutralization 
and somewhat weaker correlation between T cell response 
and neutralization. 
A lack of Ab-mediated protection in single-dose vaccinees 
could be mitigated by a broader repertoire of T cell responses 
(18). To investigate differences in T cell recognition, we de-
signed peptide pools covering the affected regions of Wuhan-
Hu-1, B.1.1.7, and B.1.351 variant sequence (table S2). We com-
pared T cell responses to these peptide pools in PBMC from 
individuals vaccinated post infection and vaccinated naïve 
(Fig. 2E). Responses in post infection vaccinees were in gen-
eral higher than in the vaccinated naïve individuals: note an 
enhanced response to the B.1.1.7 peptide pool. T cell re-
sponses were heterogeneous; responses to variant pools 
could be either higher or lower than to Wuhan Hu-1 pools. 
Alterations in affinity for the T cell receptor can lead to al-
tered peptide ligand effects and differential polarization of 
cytokine effector programs, as we have previously observed 
in Zika virus infection (19). We wondered if this was also oc-
curring for SARS-CoV-2; however, we found no evidence for 
immune deviation to interleukins (IL)-4, -5, -10,–13, 17A or 23 
(fig. S3). 
For B.1.1.7 and B.1.351, attention has centered on the 
N501Y mutation, as this is implicated in altered ACE2 bind-
ing and enhanced infectivity and transmission but is also a 
target for B and T cell recognition. We initially looked at T 
cell responses following natural infection and found that at 
16–18 weeks post infection, the N501Y mutation appeared to 
have no substantial differential impact on the T cell response 
(Fig. 2F), unlike nAb recognition (5). 
The specific impact of any T cell epitope changes on the 
immune response against VOC depends on changes in pep-
tide binding to the peptide-presenting HLA molecules. Since 
the HLA complex is the most polymorphic part of the human 
genome, any alteration to core HLA binding motifs will dif-
ferentially impact people with some HLA alleles over others. 
We performed in silico analysis (NetMHCIIpan) to predict 
which of the B.1.1.7 and B.1.351 mutations were found in HLA 
core binding motifs and how this might impact binding to 
common HLAII alleles (DRB1*0101, DRB1*0301, DRB1*0401, 
DRB1*0701, DRB1*1101, DRB1*1301, and DRB1*1501) (tables 
S3 and S4). Some of the mutations did not fall in a region 
predicted to bind the HLAII alleles tested (D3L, T716I, 
T1001I, A1708D and 3675-7 SGF del). Although several muta-
tions were not predicted to significantly change affinity for 
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affinities depending on host HLAII type (tables S3 and S4). 
Analyzing altered responses to the D1118H mutation, we 
noted that individuals who carried DRB1*0301 and 
DRB1*0401 showed enhanced T cell responses to the Wuhan 
Hu-1 peptide compared to those that did not (p = 0.0072) (Fig. 
2G). T cell responses to the variant peptide appeared to be 
reduced in individuals carrying DRB1*0301 and DRB1*0401 
(Fig. 2H). There is a basis for this in terms of differential 
HLAII binding as the D to H mutation is predicted to lose the 
T cell epitope for people carrying DRB1*0301 and DRB1*0401, 
but not for example in those who are DRB1*0701 or 
DRB1*1501 who would be predicted to show an enhanced re-
sponse (table S3). People who are DRB1*1301 are predicted to 
gain a response as a consequence of this mutation. Analyzing 
responses to the E484K mutation seen in B.1.351 and P.1 var-
iants, we noted that it did not fall in a region predicted to 
bind the HLAII alleles tested (table S4). The mutation ap-
peared to have no substantial or differential impact on T cell 
responses (Fig. 2I). 
When we primed transgenic mice expressing human 
HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool, T cell 
responses to the B.1.1.7 variant peptide pool were significantly 
reduced (p = 0.0286) (Fig. 2J). Furthermore, the T cell re-
sponse to the spike N501Y mutation common to all three of 
the current VOC was ablated. 
In this HCW cohort, vaccinated naïve individuals made an 
anti S1 RBD Ab response with a mean titer of about 100 U/ml 
at d22 (±2d) after vaccination, roughly equivalent to the 
mean peak Ab response after natural infection (14). However, 
the spike T cell response after one dose was lower than after 
natural infection, and for 30% of vaccinees no response could 
be measured. However, T cell responses are enhanced 4-fold 
in those vaccinated post-infection. This T cell enhancement 
is small relative to the 63-fold change in ASC and the corre-
sponding 140-fold change in Roche anti-S (RBD) Ab levels we 
observed after one vaccine dose in HCW vaccinated post in-
fection (14). While much has been written about the impact 
of rapidly waning serum antibody, our findings confirm MBC 
are nevertheless primed and able to contribute a rapid, large 
response to repeat exposure. The rather large effect on B cell 
priming and restimulation, relative to T cells, in previously 
infected single-dose vaccinated individuals may reflect the 
fact that, among the nuanced differences between the li-
censed COVID-19 vaccines, aspects of the mRNA adjuvant ef-
fect appear to skew immunity to high nAb titers, which may 
underpin its high efficacy. Our evidence for enhanced vaccine 
responses after infection supports the case that only one vac-
cine dose is necessary to maximize immune protection for 
SARS-CoV-2 experienced individuals (14, 20). 
It is striking that the high IC50 titers in those vaccinated 
after infection provide such a large protective margin that re-
sponses to authentic B.1.1.7 and B.1.351variants are also high. 
In contrast, nAb responses in individuals several months on 
from mild infection show much lower IC50s against B.1.1.7 
and B.1.351, often <100. Similarly, the majority of responses 
in naïve individuals after one dose show weak recognition of 
B.1.1.7 and B.1.351. This finding indicates potentially poor pro-
tection against B.1.1.7 and B.1.351 in individuals who have ex-
perienced natural infection or who have only had one vaccine 
dose. 
It is important to map the effect of VOC mutations on any 
evasion of T cell immunity. The case has been made that re-
ductions in antibody neutralization of mutant spike may be 
mitigated by protective T cells (8). A case has been made for 
the role of T cells as correlates of protection (21). Our evi-
dence from this analysis 22d (±2) after one dose is that T cell 
immunity is mostly variably low but also relatively unper-
turbed by the N501Y mutation. The other mutations we con-
sidered that overlay CD4 epitopes were, as might be 
predicted, distributed across the range of HLAII polymor-
phisms. Those alleles associated with loss of CD4 response to 
the variant pool tended to be those with a lysine in pocket 4 
of the groove (HLA-DR residue 71β), while those with an in-
creased response to the variant pool tend to be those with a 
smaller, alanine. In HLA-DRB1*0401 transgenics we con-
firmed that in the context of a given HLAII heterodimer, the 
N501Y mutation can result in ablation of this part of the T 
cell response, demonstrating that HLA polymorphisms are 
likely to be significant determinants of responder/non- 
responder status with respect to vaccine escape. 
SARS-CoV-2 immunity now encompasses post infection 
plus either zero, one or two vaccine doses and first and sec-
ond dose naïve vaccinated. Single dose vaccination post in-
fection achieves similar levels of S1 RBD binding antibodies 
to two doses in naïve vaccinated individuals and second dose 
vaccination in one dose vaccinated post infection individuals 
offers no additional enhancement (22). Moving forward, it 
will be important to resolve the quantitative and qualitative 
differences between these groups in terms of neutralizing an-
tibody repertoire as well as phenotype and durability of 
memory B and T cell responses. Durability of immunity to 
natural infection and following vaccination, as well as sus-
tained vaccine efficacy and vaccine escape need to be moni-
tored over time. 
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Fig. 1. Impact of prior natural infection with SARS-CoV-2 during the first wave on T and B cell responses to 
a single dose of the mRNA COVID-19 vaccine, BNT162b2. (A) N Ab measured by electrochemiluminescence 
immunoassay analyzer (ECLIA) in serum samples from HCW with (n = 25) and without (n = 26) laboratory 
confirmed SARS-CoV-2 infection (Wuhan Hu-1, during the first wave) 3 weeks after a single dose of the mRNA 
COVID-19 vaccine, BNT162b2. (B) Magnitude of T cell response to spike protein and spike mapped epitope 
peptides (MEP) in HCW with and without laboratory confirmed SARS-CoV-2 infection (n = 23 per group). Data 
are shown pre-vaccination (16–18 weeks after infection) and 3 weeks after the first dose vaccination (week 42) 
with line at geo mean. (C) Proportion of HCW with (n = 23) and without (n = 23) laboratory confirmed SARS-
CoV-2 infection (during the first wave) with a T cell response to Spike protein within the range (0, 1–19, 20–79, 
>80 ΔSFC/106 PBMC) before and 3 weeks after first dose vaccination. (D) Magnitude of T cell response to spike 
protein in HCW without a history of SARS-CoV-2 infection, plotted pairwise at 16–18 weeks and 42 weeks (3 
weeks after first dose vaccination). (E) Percentage of S1 specific IgG+ antibody secreting cells (ASC) in 
vaccinated HCW with (n = 23) and without (n = 22) prior SARS-CoV-2 infection and in unvaccinated HCW with 
(n = 12) and without prior infection (n = 5). Line at geo mean. (F) RBD Ab titers measured by ECLIA in serum 
samples from HCW with (n = 25) and without (n = 26) laboratory confirmed SARS-CoV-2 infection following first 
dose vaccination. (G) Neutralizing antibody titer (IC50) against Wuhan Hu-1 authentic virus in HCW with (n = 
24) and without (n = 20) laboratory confirmed SARS-CoV-2 infection. Line at arithmetic mean. (H) Correlation 
between percentage of S1 specific ASC and magnitude of T cell response to spike protein in vaccinated HCW 
with (n = 21, red) and without (n = 19, blue) a history of SARS-CoV-2 infection during the first wave. (I) Correlation 
between percentage of S1 specific ASC and RBD Ab titer in HCW with (n = 23, red) and without (n = 23, blue) a 
history of SARS-CoV-2 infection. [(A), (B), (E), and (F)] Numbers of HCW in each group with detectable 
responses are shown. [(F) and (G)] Data are shown pre-vaccination (16–18 weeks after infection) and 3 weeks 
after the first dose vaccination (week 42). [(A), (D), and (F)] Wilcoxon matched-pairs signed rank test. [(B), (C), 
(E), and (G)] Kruskal Wallis multiple comparison ANOVA with Dunn’s correction. [(H) and (I)] Spearman’s rank 
correlation. Ab, antibody; HCW, health care workers; RBD, receptor binding domain; S1, spike subunit 1; SFC, 




























Fig. 2. Impact of vaccination and prior natural infection with SARS-CoV-2 during the first wave 
on T and B cell responses to the UK B.1.1.7 and South African B.1.315 variants. (A) Neutralizing 
antibody (nAb) titer (IC50) against B.1.1.7 and B.1.351 authentic virus in HCW with (n = 24) and 
without (n = 20) laboratory confirmed SARS-CoV-2 infection (Wuhan Hu-1). Lines at arithmetic 
mean. Data are shown pre-vaccination (16–18 weeks after infection) and 3 weeks after the first 
dose vaccination (week 42). (B) nAb (IC50) titers against Wuhan Hu-1 and B.1.1.7 authentic viruses 
plotted pairwise by individual. (C) Percentage of Wuhan Hu-1 S1 and S1 containing variant 
mutations (E484K, K417N and N501Y) specific IgG+ antibody secreting cells (ASC) in vaccinated 
HCW with (n = 4) and without (n = 4) prior SARS-CoV-2 infection. (D) Correlations between nAb 
(IC50) titers of Wuhan Hu-1, B.1.1.7 or B.1.351 authentic virus and RBD Ab titer, percentage of S1 
specific ASC and magnitude of T cell response to S1 protein in vaccinated HCW with (n = 22–24, 
red) and without (n = 18–20, blue) a history of SARS-CoV-2 infection. (E) Magnitude of T cell 
response to Wuhan Hu-1, B.1.1.7 or B.1.351 peptide pools in vaccinated HCW with (n = 23 or 18) and 
without (n = 23 or 18) SARS-CoV-2 infection (Wuhan Hu-1), plotted as grouped data (median plus 
interquartile range) and pairwise for each individual. (F) Magnitude of T cell response to Wuhan 
Hu-1 S1 protein and N501Y variant spike RBD protein in unvaccinated HCW with laboratory 
confirmed SARS-CoV-2 infection (n = 14) or to Wuhan Hu-1 and N501Y mutated peptide in 
vaccinated HCW with (n = 18) and without (n = 18) a history of SARS-CoV-2 infection, plotted 
pairwise by individual. (G) Magnitude of T cell response to Wuhan Hu-1 or B.1.1.7 D1118H peptide in 
vaccinated HCW with a history of SARS-CoV-2 infection (n = 23), plotted by 
DRB1*0301/DRB1*0401 status. Lines at median plus interquartile range. (H) Magnitude of T cell 
response to Wuhan Hu-1 or B.1.1.7 D1118H peptide in vaccinated HCW with (n = 23) and without (n 
= 23) a history of SARS-CoV-2 infection plotted pairwise by individual and with individuals carrying 
DRB1*0301 or DRB1*0401 alleles marked in purple. (I) Magnitude of T cell response to Wuhan Hu-
1 or B.1.351 E484K mutated peptide in vaccinated HCW with (n = 18) and without (n = 18) a history 
of SARS-CoV-2 infection, plotted pairwise by individual. (J) Magnitude of T cell response to Wuhan 
Hu-1 (Wuh), B.1.1.7 or B.1.315 peptide pools and individual peptides in Wuhan Hu-1 peptide 
immunized HLA-DRB1*04:01 transgenic mice (left-hand panel n = 4, right-hand panel n = 8. Lines 
at arithmetic mean + SEM). (A) Kruskal Wallis multiple comparison ANOVA with Dunn’s correction. 
[(B), (C), (E) – right-hand panels, (F), (H), and (I)] Wilcoxon matched-pairs signed rank test. (D) 
Spearman’s rank correlation. [(E) – left-hand panels, (G), and (J)] Mann-Whitney U test. ASC, 
antibody secreting cells; HCW, health care workers; RBD, receptor binding domain; S1, spike 
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